Effects of Glimepiride vs Glibenclamide on Ischaemic Heart Disease Risk Factors and Glycaemic Control in Patients with Type 2 Diabetes Mellitus

被引：0
|
作者：
M. E. Britton
A. E. Denver
V. Mohamed-Ali
J. S. Yudkin
机构：
[1] University College London Medical School and Royal Free Hospital School of Medicine,Joint Department of Medicine, Whittington Hospital
来源：
Clinical Drug Investigation | 1998年 / 16卷
关键词：
Adis International Limited; Fast Plasma Glucose; Glibenclamide; Proinsulin; Sulphonylurea;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: This study aimed to compare the effects of glimepiride and glibenclamide on glycaemic control and a range of risk factors for ischaemic heart disease (IHD), including concentrations of insulin-like molecules.
引用
收藏
页码：303 / 317
页数：14
相关论文
共 50 条
  • [1] Effects of glimepiride vs glibenclamide on ischaemic heart disease risk factors and glycaemic control in patients with type 2 diabetes mellitus
    Britton, ME
    Denver, AE
    Mohamed-Ali, V
    Yudkin, JS
    CLINICAL DRUG INVESTIGATION, 1998, 16 (04) : 303 - 317
  • [2] An audit of glycaemic control and cardiovascular risk factors in patients with type 2 diabetes mellitus
    P. Downey
    L. O’Shea
    D. Dillon
    M. Corbett
    S. Sreenan
    Irish Journal of Medical Science, 2002, 171 (Suppl 5) : 11 - 12
  • [3] Efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus and inadequate glycaemic control on glimepiride monotherapy
    Strojek, K.
    Hruba, A.
    Elze, M.
    Langkilde, A.
    Parikh, S.
    DIABETOLOGIA, 2010, 53
  • [4] Pioglitazone vs. glibenclamide: Significant differences in glycaemic control and treatment failure rates in patients with type-2-diabetes mellitus
    Markolf, Hanefeld
    Luebben, Georg
    Pfuetzner, Andreas
    Forst, Thomas
    DIABETES, 2006, 55 : A144 - A144
  • [5] An audit of glycaemic control and cardiovascular risk factors in patients with type 1 diabetes mellitus
    P. Downey
    L. O’Shea
    D. Dillon
    M. Corbett
    S. Sreenan
    Irish Journal of Medical Science, 2002, 171 (Suppl 5) : 11 - 11
  • [6] Comparison of the effects of glimepiride and glibenclamide on lipid metabolism in patients with type 2 diabetes
    Matsui, J.
    Ogawa, Y.
    Tamasawa, N.
    Matsuki, K.
    Tanabe, J.
    Murakami, H.
    Suda, T.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 506 - 506
  • [7] Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus
    Xu, Dan-yan
    Zhao, Shui-Ping
    Huang, Qiu-xia
    Du, Wei
    Liu, Yu-hua
    Liu, Ling
    Xie, Xiao-mei
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 88 (01) : 71 - 75
  • [8] Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes
    Tan, MH
    Johns, D
    Strand, J
    Halse, J
    Madsbad, S
    Eriksson, JW
    Clausen, J
    Konkoy, CS
    Herz, M
    DIABETIC MEDICINE, 2004, 21 (08) : 859 - 866
  • [9] Emerging risk factors for coronary heart disease in patients with Type 2 diabetes mellitus
    Merkouris, P
    Sotiropoulos, A
    Skourtis, S
    Dimitriou, K
    Apostolou, O
    Politakis, P
    Kontela, E
    Pappas, S
    DIABETOLOGIA, 2004, 47 : A415 - A416
  • [10] Glimepiride and ischemic heart disease in diabetes mellitus Type 2: effects on the ischemic threshold.
    Aleksandrov, A
    Bondarenko, I
    Kukharenko, S
    Yadrikhinskaj, M
    Solovjeva, O
    Dedov, I
    DIABETOLOGIA, 2003, 46 : A281 - A281
12345